Medicine Recommendations

Chronic Neuropathic Pain

Vitreomacular traction (NICE TA297)

NICE TA297 - Ocriplasmin for treating vitreomacular traction

Unlicensed use in non-acute treatment of recurrent gastrointestinal bleeding disorders (including angiodysplasia, small bowel dysplasia, gastric antral vascular ectasia, haemorrhagic telangiectasia)

Unlicensed use for orthostatic intolerance disorders e.g. postural orthostatic tachycardia syndrome (PoTS)

Unlicensed use in Secretory Gastrointestinal Disorders (e.g. enterocutaneous fistula, high output stoma and refractory diarrhoea)

Treatment and prophylaxis of schizophrenia

Schizophrenia

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Rapid tranquilization

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

COPD

Chronic spontaneous urticaria (NICE TA339)

NICE TA339 - Omalizumab for previously treated chronic spontaneous urticaria

Primary and secondary prevention of cardiovascular disease

Parkinson’s disease – adjunctive therapy in adults with end-of-dose motor fluctuations who cannot be stabilised on preparations of levodopa/DOPA decarboxylase inhibitors

For Non – Cystic Fibrosis Bronchiectasis

Influenza treatment & prophylaxis (NICE TA158 & 168)

NICE TA158 - Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza

NICE TA168 - Amantadine, oseltamivir and zanamivir for the treatment of influenza

Vulvovaginal or vaginal atrophy in postmenopausal women

Anxiety (short term use)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Treatment of epilepsy

MHRA Drug Safety Update - Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions

MHRA Drug Safety Update - Antiepileptic drugs: updated advice on switching between different manufacturers’ products

Pain

Restless Legs Syndrome

Chronic pain